NCT07533786 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery
| NCT ID | NCT07533786 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Condition | Pain After Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-05-22 |
| Primary Completion | 2026-11-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 200 participants in total. It began in 2026-05-22 with a primary completion date of 2026-11-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-center, randomized, double-blind, double-dummy, placebo/active-controlled study. 200 subjects undergoing abdominal surgery under general anesthesia are planned to be enrolled and randomized into the HSK55718 group, morphine group, and placebo group.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years old, regardless of gender; * 18 kg/m2≤BMI≤30 kg/m2; * American Society of Anesthesiologists (ASA) gradeⅰ-ⅲ; * Accept abdominal surgery under general anesthesia; * Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time; * Fully understand and voluntarily participate this trial, and sign the informed consent form; Exclusion Criteria: * A history of cardiovascular, respiratory, neurological, or psychiatric diseases that meet the protocol-defined exclusion criteria. * Clinically significant abnormalities in laboratory tests during the screening period. * A history of severe drug allergy or known allergy to the investigational drug. * Continuous use of opioid analgesics for more than 10 days for any reason within 3 months prior to randomization. * Use of any medication that may affect analgesia, where the last dose was administered less than 5 half-lives of that drug before randomization. * A history of drug abuse, substance abuse, and/or alcohol abuse within the past year. * Pregnant or lactating women. * Participation in another drug clinical trial within 3 months prior to the screening period. * Presence of any sensory dysfunction. * Presence of any painful physical condition. * Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07533786 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pain After Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07533786 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07533786 currently recruiting?
Yes, NCT07533786 is actively recruiting participants. Contact the research team at wangyr@haisco.com for enrollment information.
Where is the NCT07533786 trial being conducted?
This trial is being conducted at Changsha, China, Chengdu, China.
Who is sponsoring the NCT07533786 clinical trial?
NCT07533786 is sponsored by Haisco Pharmaceutical Group Co., Ltd.. The trial plans to enroll 200 participants.